Multiple sclerosis (MS) involves damage to the insulating layer that covers nerves – which is tissue that regenerates very slowly in the central nervous system. However, the human body does not leave “blank” spaces, instead filling them with fibrous tissue (in other words scar tissue) that does not have insulating properties. Nerve signals are not transmitted properly through such tissue.
A patient with this condition first begins to feel disorders of the nervous system that will gradually become more pronounced as the disease progresses. The greater the disability, the less likely it is that the scar tissue will be prevented from forming. This process can be stimulated, but the immune system’s inadequate functioning needs to be dealt with before that.
T-cell product (TCV) is used to treat multiple sclerosis. These cells allow a doctor to stop the immune system’s response to the nerve-covering insulating layer of myelin. Preparations are created individually for each patient by harvesting the T-cells responsible for the disease’s progression from their blood in the laboratory.
The product stimulates an immune response against the T-cells. Specifically, new T-cells are introduced into the body that kills the myelin-specific T cells. This technology has been used worldwide for more than 10 years to regulate the immune response in people with multiple sclerosis.
This method of multiple sclerosis treatment is performed only at a healthcare institution in cases for which a doctor prescribes this preparation for a patient.
See our leaflet for more information.